Ravit Arav-Boger¹, Yuval S. Boger², Charles B. Foster³ and Zvi Boger²

¹Department of Pediatrics, Division of Infectious Diseases, Johns Hopkins Hospital, Baltimore. ²Optimal Neural Informatics, Pikesville. ³Department of Pediatrics, Division of Infectious Diseases, The Cleveland Clinic, Cleveland, OH.

Abstract

A large number of CMV strains has been reported to circulate in the human population, and the biological significance of these strains is currently an active area of research. The analysis of complex genetic information may be limited using conventional phylogenetic techniques. We constructed artificial neural networks to determine their feasibility in predicting the outcome of congenital CMV disease (defined as presence of CMV symptoms at birth) based on two data sets: 54 sequences of CMV gene UL144 obtained from 54 amniotic fluids of women who contracted acute CMV infection during their pregnancy, and 80 sequences of 4 genes (US28, UL144, UL146 and UL147) obtained from urine, saliva or blood of 20 congenitally infected infants that displayed different outcomes at birth. When data from all four genes was used in the 20-infants’ set, the artificial neural network model accurately identified outcome in 90% of cases. While US28 and UL147 had low yield in predicting outcome, UL144 and UL146 predicted outcome in 80% and 85% respectively when used separately. The model identified specific nucleotide positions that were highly relevant to prediction of outcome. The artificial neural network classified genotypes in agreement with classic phylogenetic analysis. We suggest that artificial neural networks can accurately and efficiently analyze sequences obtained from larger cohorts to determine specific outcomes.

The ANN training and analysis code is commercially available from Optimal Neural Informatics (Pikesville, MD).